Reply to Chang and Yew

Affiliations

¹ University of Sassari Sassari, Italy.
² Istituti Clinici Scientifici Maugeri-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Tradate, Italy.
³ Research Institute of the McGill University Health Centre Montreal, Québec, Canada.
⁴ Independent Consultant San Francisco, California.
⁵ Centers for Disease Control and Prevention Atlanta, Georgia.
⁶ University of Texas Health Science Center Tyler, Texas and.
⁷ University of California San Francisco San Francisco, California.

Comment

Giovanni Sotgiu et al. Am J Respir Crit Care Med. 2020.

. 2020 Sep 1;202(5):778-779.

doi: 10.1164/rccm.202003-0698LE.

¹ University of Sassari Sassari, Italy.
² Istituti Clinici Scientifici Maugeri-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Tradate, Italy.
³ Research Institute of the McGill University Health Centre Montreal, Québec, Canada.
⁴ Independent Consultant San Francisco, California.
⁵ Centers for Disease Control and Prevention Atlanta, Georgia.
⁶ University of Texas Health Science Center Tyler, Texas and.
⁷ University of California San Francisco San Francisco, California.

No abstract available

Comment on

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR Jr, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B. Nahid P, et al. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST. Am J Respir Crit Care Med. 2019. PMID: 31729908 Free PMC article.
ATS/CDC/ERS/IDSA Clinical Practice Guidelines for Treatment of Drug-Resistant Tuberculosis: A Two-edged Sword?
Chang KC, Yew WW. Chang KC, et al. Am J Respir Crit Care Med. 2020 Sep 1;202(5):777-778. doi: 10.1164/rccm.201912-2460LE. Am J Respir Crit Care Med. 2020. PMID: 32374633 Free PMC article. No abstract available.

1. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis: an official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019;200:e93–e142. - PMC - PubMed
1. Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, et al. Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392:821–834. - PMC - PubMed
1. World Health Organization. WHO consolidated guidelines on drug- resistant tuberculosis treatment. Geneva, Switzerland: World Health Organization; 2019. - PubMed
1. Lange C, Duarte R, Fréchet-Jachym M, Guenther G, Guglielmetti L, Olaru ID, et al. European MDR-TB database collaboration. Limited benefit of the new shorter multidrug-resistant tuberculosis regimen in Europe. Am J Respir Crit Care Med. 2016;194:1029–1031. - PubMed
1. Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, et al. Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico. Eur Respir J. 2018;51:1702267. - PubMed